TMCnet News
Research and Markets: Heplisav: 1018 ISS Immunostimulatory Oligonucleotide with HBsAg (Prophylactic Hepatitis B Virus Vaccines) - Global Forecast and Market Analysis to 2022DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/l8hslp/heplisav) has announced the addition of the "Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022" report to their offering. Heplisav [Hepatitis B vaccine, 1018 ISS immunostimulatory oligonucleotide with HBsAg (HBsAg-1018)] is Dynavax Technologies' adjuvanted pipeline vaccine candidate that guards adults against acute and chronic infections caused by all known strains of HBV, with a particular emphasis on protecting adults that have failed to achieve seroconversion from the currently licensed HBV vaccines. With Heplisav, Dynavax hopes to address a key clinical unmet need in the treatment landscape while simultaneously improving HBV vaccination coverage in adults. Scope
Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Overview 3.2 Etiology and Pathophysiology 3.3 Symptoms 4 Vaccination Recommendations and Coverage Rates 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment 6 Opportunity and Unmet Need 6.1 Overview 6.2 Increased Vaccine Immunogenicity 6.3 Increased Vaccination Coverage Rates 6.4 Increased Patient Awareness 6.5 Improved Physician Education 6.6 More Cost-Effective Vaccines 7 Pipeline Assessment 8 Heplisav 8.1 Overview 8.2 Immunogenicity 8.3 Safety 8.4 Dosing and Formulation 8.5 Potential Clinical Positioning 8.6 Potential Commercial Positioning 8.7 Pricing and Reimbursement 8.8 SWOT Analysis 8.9 Forecast 9 Appendix For more information visit http://www.researchandmarkets.com/research/l8hslp/heplisav
|